


## CLAIMS

1. A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic.

2. A pharmaceutical composition according to claim 1, wherein the insulin sensitizer is a compound of the formula:



wherein R represents a hydrocarbon group or a heterocyclic group, each of which may be substituted; Y represents a group of the formula:  $-\text{CO}-$ ,  $-\text{CH}(\text{OH})-$  or  $-\text{NR}^3-$  where  $\text{R}^3$  represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur;  $\text{R}^1$  represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with  $\text{R}^1$ ; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof.

3. A pharmaceutical composition according to claim 1, wherein the insulin sensitizer is pioglitazone hydrochloride, troglitazone, rosiglitazone or 4-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl]isoxazolidin-3,5-dione.

4. A pharmaceutical composition according to claim 2, wherein the compound of the formula (I) or salt thereof is pioglitazone hydrochloride.

5. A pharmaceutical composition according to claim 1, wherein the anorectic is a central anorectic.

6. A pharmaceutical composition according to claim 5,  
wherein the central anorectic is mazindol.
- 5 7. A pharmaceutical composition according to claim 1,  
wherein the insulin sensitizer is pioglitazone  
hydrochloride and the anorectic is mazindol.
8. A pharmaceutical composition according to claim 1,  
10 which is for preventing or treating diabetes.
9. A pharmaceutical composition according to claim 8,  
wherein the diabetes is noninsulin-dependent diabetes  
mellitus.
- 15 10. A pharmaceutical composition according to claim 2,  
wherein the compound of the formula (I) or salt thereof is  
troglitazone.
- 20 11. A pharmaceutical composition according to claim 2,  
wherein the compound of the formula (I) or salt thereof is  
rosiglitazone or its maleate.
- 25 12. A pharmaceutical composition according to claim 1,  
which is for preventing or treating diabetic complications.
13. A pharmaceutical composition according to claim 1,  
which is for preventing or treating impaired glucose  
tolerance.
- 30 14. A pharmaceutical composition which comprises an  
insulin sensitizer and is used in combination with an  
anorectic.
- 35 15. A method for preventing or treating diabetes in a  
mammal in need thereof, which comprises administering to

said mammal an effective amount of an insulin sensitizer in combination with an anorectic.

16. A method for preventing or treating diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effective amount of an insulin sensitizer in combination with an anorectic.

17. A method for preventing or treating impaired glucose tolerance in a mammal in need thereof, which comprises administering to said mammal an effective amount of an insulin sensitizer in combination with an anorectic.

18. Use of an insulin sensitizer for the manufacture of a pharmaceutical preparation for treating diabetes which is used in combination with an anorectic.

19. Use of an insulin sensitizer for the manufacture of a pharmaceutical preparation for treating diabetic complications which is used in combination with an anorectic.

20. Use of an insulin sensitizer for the manufacture of a pharmaceutical preparation for treating impaired glucose tolerance which is used in combination with an anorectic.

21. A method for reducing the side effects of an insulin sensitizer or/and an anorectic administered to a diabetic mammal, which comprises administering to said mammal an effective amount of them.